JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

NCT06380348 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

398

Enrollment

INDUSTRY

Sponsor class

Conditions

Local Advanced or Metastatic NSCLC

Interventions

DRUG: JMT101 Injection
DRUG: Osimertinib tablet
DRUG: Cisplatin injection
DRUG: Pemetrexed injection

Sponsor

Shanghai JMT-Bio Inc.